Vivimed Labs Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.

Vivimed Labs reported weak Q3 FY26 results with standalone revenue from operations of ₹116.31 million, down sharply from ₹186.59 million in the previous quarter and ₹312.33 million in Q3 FY25. For the nine months ended December 2025, standalone revenue fell to ₹482.33 million from ₹810.29 million a year ago, a drop of about 40%. The company swung to a standalone loss before tax of ₹165.66 million in Q3 FY26 and a cumulative 9-month loss of ₹279.09 million, compared to a profit of ₹577.90 million in 9M FY25. Consolidated nine-month PAT was a loss of ₹293.49 million versus a profit of ₹198.05 million last year. The statutory auditor SVRL & Co. issued a qualified conclusion, flagging that the company has not provided for interest, penal interest and penal charges of approximately ₹164.52 million for the quarter (₹472.37 million year-to-date) on term and working capital loans, which understates liabilities and losses. The auditor also noted a pending evaluation of a forensic audit report from FY 2022-23 and insufficient evidence for a ₹46.03 million commission provision based on proforma invoices.